What did @xode.anna actually say?
Anna reported losing 11 pounds in her first month on tirzepatide (Zepbound) at the 2.5 mg starting dose, dropping from 206 to 195 pounds. She corrected herself in the caption after saying 205 on camera. She is now stepping up to 5 mg and filmed herself injecting into her abdomen, a few inches from the belly button, without letting the pen warm to room temperature first.
She also mentioned drinking protein shakes and electrolytes, specifically Gatorade Zero, on injection day. No claims about cures or medical conditions were made beyond the hashtag reference to insulin resistance. The video is a personal progress update, not medical advice, and she presents it that way.
Does the science back this up?
Eleven pounds in month one is on the higher end of typical but not implausible. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed average weight loss of about 20.9% of body weight over 72 weeks with tirzepatide 15 mg. Early months tend to produce faster loss before the curve flattens.
A 2023 analysis by Garvey et al. in Nature Medicine found that patients on tirzepatide lost roughly 5-7% of body weight in the first 12 weeks across dose escalation phases. At 206 pounds, 11 pounds represents about 5.3%, which sits squarely within that range. So the number checks out.
The stomach injection site she demonstrates is clinically appropriate. The FDA-approved prescribing information for Zepbound confirms the abdomen as a valid site. Her note about not warming the pen is a minor comfort issue, not a safety one. Room-temperature injections may sting more but do not affect drug efficacy or pharmacokinetics meaningfully.
What did they get wrong (or right)?
She got the results roughly right, and her injection technique looks reasonable from what is visible. The protein and electrolyte strategy on injection day is also not unfounded. Some clinicians recommend adequate hydration and protein intake to mitigate nausea and preserve lean mass during GLP-1 therapy.
What she got slightly wrong: her framing that not having side effects on 2.5 mg means she probably will not have them on 5 mg. That is not how dose escalation works. The SURMOUNT-1 data showed that GI adverse events, primarily nausea, vomiting, and diarrhea, increased at higher doses. About 31% of patients on 10 mg and 15 mg reported nausea versus a lower rate at starting doses. Expecting 5 mg to behave like 2.5 mg is wishful thinking.
She also mentions the hashtag "insulin resistance" but never addresses it on camera. Tirzepatide does improve insulin sensitivity through its dual GIP and GLP-1 mechanism, but that is not a claim she made verbally, so there is nothing to fact-check there.
What should you actually know?
If you are watching this and thinking "I want those results," a few things are worth knowing. First, early weight loss on tirzepatide is partly water weight and glycogen depletion, not exclusively fat. Studies suggest the composition shifts over time, which is why preserving protein intake, as Anna is doing, matters.
Second, dose escalation is where most people experience their first real side effects. The jump from 2.5 mg to 5 mg is the first escalation in the standard titration schedule. If nausea or vomiting hits hard enough to disrupt eating and hydration, that needs clinical attention, not just electrolyte drinks.
Third, 11 pounds in a month is motivating but not a benchmark you should hold yourself to. Individual response to tirzepatide varies significantly based on baseline metabolic health, adherence, diet, and activity. Comparing your month-one results to someone else's is a fast path to unnecessary frustration.
Finally, Zepbound is a prescription medication. None of what Anna shares here substitutes for working with a prescribing provider who can monitor your response and adjust your plan.